RaySearch Laboratories AB (publ) appoints Professor Antony Lomax, one of the world’s most respected pioneers in proton therapy, to support the company’s strategic development in particle therapy and emerging treatment technologies. The appointment further strengthens RaySearch’s position in a clinically advanced and strategically important growth area.
Antony Lomax has played a defining role in the evolution of modern proton therapy. At the Paul Scherrer Institute (PSI) in Switzerland, where he has worked for more than three decades, he was part of the pioneering team that helped transform proton therapy from an experimental concept into an established clinical standard. He was instrumental in the development of pencil-beam scanning and intensity-modulated proton therapy (IMPT), including the world’s first clinical IMPT treatment at PSI in 1999.
With a long track record of scientific leadership, innovation, and collaboration across the international proton therapy community, Antony Lomax brings deep expertise to RaySearch.
“RaySearch combines deep scientific capabilities with a clear ambition to shape the future of radiation oncology. I look forward to contributing my experience in proton therapy as RaySearch continues to advance particle treatments and get the possibility to explore new treatment modalities,” says Antony Lomax.
“Antony Lomax is widely regarded as one of the pioneers in proton therapy, and his experience and reputation in the field will be tremendously valuable to us. As particle therapy becomes increasingly important, his perspective will help further strengthen our position and deepen our relevance for customers, partners, investors, and the broader oncology community,” comments Johan Löf, founder and CEO of RaySearch.
Antony Lomax will assume the role of Clinical Ambassador Particle Therapy at RaySearch on August 12, 2026, as part of the newly established Corporate Development and Strategy department.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch’s software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.